Pharmacological interventions in the newborn piglet in the first 24 h after hypoxia-ischemia. A hemodynamic and electrophysiological perspective

Exp Brain Res. 2002 Nov;147(2):200-8. doi: 10.1007/s00221-002-1182-x. Epub 2002 Sep 28.

Abstract

The purpose of this study was to investigate whether combined inhibition of neuronal and inducible nitric oxide synthase (NOS) by 2-iminobiotin, free radical scavenging by allopurinol, and non-protein-bound iron chelation with deferoxamine improved cerebral oxygenation, electrocortical brain activity, and brain energy status during the first 24 h after hypoxia-ischemia (HI) in the newborn piglet. Forty-three newborn piglets were subjected to 1 h of severe HI by occluding both carotid arteries and phosphorous magnetic resonance spectroscopy ((31)P-MRS)-guided hypoxia, whereas five served as sham-operated controls. Upon reperfusion, piglets received vehicle (n=12), 2-iminobiotin (n=11), allopurinol (n=10), or deferoxamine (n=10). Cerebral oxygenation was recorded with near-infrared spectrophotometry (NIRS), electrocortical brain activity was assessed with amplitude-integrated EEG (aEEG), and cerebral energy status with (31)P-MRS. The oxygenated hemoglobin (HbO(2)) and total hemoglobin (tHb) were significantly increased in vehicle-treated piglets compared with 2-iminobiotin-treated and deferoxamine-treated piglets. No change in deoxygenated Hb (HHb) was demonstrated over time. The aEEG was significantly preserved in 2-iminobiotin- and deferoxamine-treated piglets compared with vehicle-treated piglets. Allopurinol treatment was not as effective as 2-iminobiotin treatment after HI. Phosphocreatine/inorganic phosphate ratios (PCr/P(i)) were significantly decreased for vehicle-treated piglets at 24 h post-HI, whereas 2-iminobiotin, allopurinol, and deferoxamine prevented the development of secondary energy failure. We speculate that the beneficial effects, especially of 2-iminobiotin, but also of deferoxamine, are due to reduced peroxynitrite-mediated oxidation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allopurinol / pharmacology
  • Animals
  • Animals, Newborn
  • Biotin / analogs & derivatives*
  • Biotin / pharmacology
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / physiopathology*
  • Deferoxamine / pharmacology
  • Electroencephalography
  • Enzyme Inhibitors / pharmacology
  • Free Radical Scavengers / pharmacology
  • Hemoglobins / metabolism*
  • Hypoxia-Ischemia, Brain / blood
  • Hypoxia-Ischemia, Brain / drug therapy*
  • Hypoxia-Ischemia, Brain / physiopathology*
  • Iron Chelating Agents / pharmacology
  • Magnetic Resonance Spectroscopy / methods
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase Type II
  • Phosphorus Radioisotopes
  • Spectrophotometry
  • Swine
  • Time Factors

Substances

  • Enzyme Inhibitors
  • Free Radical Scavengers
  • Hemoglobins
  • Iron Chelating Agents
  • Phosphorus Radioisotopes
  • Allopurinol
  • Biotin
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase Type II
  • 2-iminobiotin
  • Deferoxamine